345 related articles for article (PubMed ID: 8191116)
1. [Comparative in vitro activity of new oral macrolides against Streptococcus pyogenes strains].
Prado V; Romero J; Herrera N; Marinkovic K; Bustos R
Rev Med Chil; 1993 Oct; 121(10):1128-34. PubMed ID: 8191116
[TBL] [Abstract][Full Text] [Related]
2. [Isolated susceptibility of Streptococcus pyogenes to 3 macrolides].
Sakran W; Raz R; Colodner R; Keness Y
Harefuah; 1997 Nov; 133(9):365-6, 414. PubMed ID: 9418339
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of Streptococcus pyogenes to two macrolides in northern Israel.
Sakran W; Raz R; Chazan B; Koren A; Colodner R
Int J Antimicrob Agents; 2004 May; 23(5):517-9. PubMed ID: 15120735
[TBL] [Abstract][Full Text] [Related]
4. Oral antimicrobial susceptibilities of Streptococcus pyogenes recently isolated in five countries.
Bandak SI; Turnak MR; Allen BS; Bolzon LD; Preston DA
Int J Clin Pract; 2000 Nov; 54(9):585-8. PubMed ID: 11220986
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro.
Van Asselt GJ; Sloos JH; Mouton RP; Van Boven CP; Van de Klundert JA
J Med Microbiol; 1995 Nov; 43(5):386-91. PubMed ID: 7563004
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibility and macrolide resistance genes in Streptococcus pyogenes collected in Austria and Hungary.
Gattringer R; Sauermann R; Lagler H; Stich K; Buxbaum A; Graninger W; Georgopoulos A
Int J Antimicrob Agents; 2004 Sep; 24(3):290-3. PubMed ID: 15325435
[TBL] [Abstract][Full Text] [Related]
7. [Emergence of resistance to macrolides in Streptococcus pyogenes].
Vinagre C; Cifuentes M; Valdivieso F; Ojeda A; Prado V
Rev Med Chil; 1999 Dec; 127(12):1447-52. PubMed ID: 10835751
[TBL] [Abstract][Full Text] [Related]
8. [Antibiotic sensitivity of Streptococcus pyogenes in pediatrics].
Gené A; González-Cuevas A; Juncosa T; Luaces C; Latorre C
Enferm Infecc Microbiol Clin; 1998; 16(6):272-4. PubMed ID: 9763744
[TBL] [Abstract][Full Text] [Related]
9. [Susceptibility of Streptococcus pyogenes isolates from pharyngeal exudates in Cordoba (Spain)].
Gordillo RM; Lacasa MJ; Ibarra A; Rodríguez F; Casal M
Rev Esp Quimioter; 2003 Mar; 16(1):58-60. PubMed ID: 12750758
[TBL] [Abstract][Full Text] [Related]
10. High macrolide resistance in Streptococcus pyogenes strains isolated from children with pharyngitis in China.
Liu X; Shen X; Chang H; Huang G; Fu Z; Zheng Y; Wang L; Li C; Liu L; Shen Y; Yang Y
Pediatr Pulmonol; 2009 May; 44(5):436-41. PubMed ID: 19360846
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes.
Amábile-Cuevas CF; Hermida-Escobedo C; Vivar R
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S30-2. PubMed ID: 11249826
[TBL] [Abstract][Full Text] [Related]
12. Nationwide survey in Italy of treatment of Streptococcus pyogenes pharyngitis in children: influence of macrolide resistance on clinical and microbiological outcomes. Artemis-Italy Study Group.
Varaldo PE; Debbia EA; Nicoletti G; Pavesio D; Ripa S; Schito GC; Tempera G
Clin Infect Dis; 1999 Oct; 29(4):869-73. PubMed ID: 10589905
[TBL] [Abstract][Full Text] [Related]
13. Resistance to erythromycin and rising penicillin MIC in Streptococcus pyogenes in India.
Capoor MR; Nair D; Deb M; Batra K; Aggarwal P
Jpn J Infect Dis; 2006 Oct; 59(5):334-6. PubMed ID: 17060703
[TBL] [Abstract][Full Text] [Related]
14. [Susceptibility of Streptococcus pyogenes to macrolides and quinolones in Guadalajara, Spain].
Rodríguez-Zurita ME; Solís del Baño S; Robres Guillén P; González Praetorius A; Gimeno Fernández C; Pérez Pomata MT; Bisquert Santiago J
Rev Esp Quimioter; 2003 Mar; 16(1):61-4. PubMed ID: 12750759
[TBL] [Abstract][Full Text] [Related]
15. [Streptococcus pyogenes: in vitro susceptibility to several antimicrobials in two date periods].
Giglio MS; Robles M; Rioseco ML; Vidal A; Segovia L
Rev Med Chil; 1996 Jun; 124(6):715-9. PubMed ID: 9041729
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of midecamycin diacetate, a 16-membered macrolide, against Streptococcus pyogenes isolated in France, 1995-1999.
Schlegel L; Merad B; Rostane H; Broc V; Bouvet A
Clin Microbiol Infect; 2001 Jul; 7(7):362-6. PubMed ID: 11531981
[TBL] [Abstract][Full Text] [Related]
17. [Antibiotic sensitivity of strains of group A beta-hemolytic streptococci isolated recently].
Alós JI; González-Palacios R; Cuadros JA; Escobar JC
Med Clin (Barc); 1990 Jan; 94(1):12-4. PubMed ID: 2186225
[TBL] [Abstract][Full Text] [Related]
18. [Emergence of macrolide resistant Streptococcus pyogenes strains in pediatric patients in France].
Mariani-Kurkdjian P; Doit C; Deforche D; Brahimi N; Francois M; Van den Abbeele T; Bingen E
Pathol Biol (Paris); 2004 Oct; 52(8):489-92. PubMed ID: 15465270
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the degree of susceptibility of Streptococcus pyogenes erythromycin-resistant strains to rokitamycin (a 16-membered macrolide) using the Epsilometer test.
Crotti D; Rossetti R; Braga PC
Drugs Exp Clin Res; 2004; 30(1):17-26. PubMed ID: 15134387
[TBL] [Abstract][Full Text] [Related]
20. Activity of ceftibuten, cefaclor, azithromycin, clarithromycin, erythromycin and telithromycin against Streptococcus pyogenes clinical isolates with different genotypes and phenotypes.
Drago L; Ripa S; Zampaloni C; De Vecchi E; Vitali LA; Petrelli D; Prenna M
Chemotherapy; 2005 Aug; 51(5):268-71. PubMed ID: 16088124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
